Generic Name and Formulations:
Alogliptin 6.25mg, 12.5mg, 25mg; tabs.

Company:
Takeda Pharmaceuticals North America, Inc
Indications for NESINA:
As adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of use: not for treatment of type 1 diabetes or diabetic ketoacidosis.

Adult Dose for NESINA:
25mg once daily. Renal impairment: moderate (CrCl ≥30–<60mL/min): 12.5mg once daily; severe (CrCl ≥15–<30mL/min) or ESRD (CrCl <15mL/min or need hemodialysis): 6.25mg once daily.

Children's Dose for NESINA:
Not established.

Pharmacological Class:
Dipeptidyl peptidase-4 (DPP-4) inhibitor.

Warnings/Precautions:
Monitor for signs/symptoms of pancreatitis; discontinue if suspected. History of angioedema with other DPP-4 inhibitors. Discontinue if serious hypersensitivity reaction is suspected. Hepatic impairment. Obtain liver function tests before starting therapy; interrupt and eva luate if liver enzymes elevated or abnormal tests persist; do not restart if liver injury is confirmed and no other etiology can be found. Monitor renal function prior to therapy and periodically thereafter. Pregnancy (Cat. B). Nursing mothers.

Interactions:
Concomitant sulfonylurea or insulin: may need lower dose of sulfonylurea or insulin to reduce risk of hypoglycemia.

Adverse Reactions:
Nasopharyngitis, headache, upper respiratory tract infection.

How Supplied:
6.25mg—30, 90; 12.5mg, 25mg—30, 90, 500